Signal Pharma to develop new treatments for major diseases

Published: 12-Mar-2012
Research & Development Cardiovascular Pharmaceutical

Aberdeen University spin out will focus on breast cancer, heart failure, diabetes and chronic pain

The University of Aberdeen is working with Scottish entrepreneur Dr Derek Douglas CBE to spin out a company that will develop new drugs to treat breast cancer, heart failure, diabetes and chronic pain.

Signal Pharma will be the first company to be spun out from the University’s Kosterlitz Centre for Therapeutics, which is focused on translating biological innovation into new ways of treating, diagnosing and understanding diseases.

The founders of the company are pharmacology expert Professor Ruth Ross and Dr Iain Greig, a medicinal chemist who helped found another University spin out that is developing drugs to treat rheumatoid arthritis. They have joined forces with cardiologist Professor Michael Frenneaux, and molecular imaging expert Professor Matteo Zanda. Dr Derek Douglas, chairman and ceo of Adam Smith Ltd is providing financial and business acumen, while Dr Michael Wyllie, founder and director Global Pharma Consulting, will provide drug development expertise.

Sigma Pharma will develop a portfolio of four drug discovery projects based on new pathways and targets identified by the University of Aberdeen scientists.

The firm is seeking to raise £1.5m to develop these projects over a period of three years.

Prof Ross, who is also director of the University’s Kosterlitz Centre, said: ‘The creation of Signal Pharma is a great opportunity to generate both medical and economic benefits based on the world class biomedical research of discoveries of the University of Aberdeen.’

Dr Greig added: ‘It is particularly satisfying to see ideas that we have worked on for many years reaching the next stage of the development process, which we hope will eventually lead to new drugs that give real benefits to the patients, saving lives and reducing suffering.’

See more

You may also like

Research & Development

New company created to develop novel technology to treat diabetes

Read more
Islexa technology has the potential to bring islet transplant therapy to treat type 1 diabetes

Trending Articles

  1. Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    UK clinical trial reforms come into force in largest regulatory overhaul in 20 years The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
  3. Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle
  4. UK REACH reform falls short as industry warns of £500m+ compliance bill The UK chemicals industry has condemned the Government's long-awaited response to the UK REACH Alternative Transitional Registration model consultation, arguing it does little to support growth or innovation
  5. AstraZeneca's tozorakimab succeeds in third pivotal Phase III COPD trial The positive results have shown that tozorakimab significantly reduced moderate-to-severe COPD exacerbations, adding to the earlier positive results from the OBERON and TITANIA trials and further supporting its potential as a first-in-class IL-33-targeting biologic

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Research & Development

New company created to develop novel technology to treat diabetes

Islexa technology has the potential to bring islet transplant therapy to treat type 1 diabetes
Research & Development

Aberdeen University wins £5.1m grant to tackle fungal infections

New strategies needed to combat life-threatening invasive fungal infections
Research & Development

Drug discovery centre to open in Aberdeen

Kosterlitz Centre for Therapeutics will take ideas from bench to bedside
Research & Development

Scientists develop new technique to fight antimicrobial resistance

The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections
Research & Development

Lancet Oncology Commission launches to examine future of academic cancer clinical trials amid funding and regulatory pressures

A global coalition of clinical investigators and patient representatives has launched the Lancet Oncology Commission to address the value and challenges of independent academic cancer clinical trials, amid growing concerns over regulatory complexity, limited public funding and the need for new international collaboration models
Regulatory

WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants

The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Subscribe now